Companies › Shattuck Labs
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology, Other; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SL-325 DR3 blocking antibody | TNFRSF25 | Phase 2 | Crohn's Disease; Healthy Volunteers | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07158437 | SL-325 | Phase 1 | Healthy Volunteers | Other | Jul 2026 |
| NCT07753850 | SL-325 | Phase 2 | Crohn's Disease | Immunology | Jul 2028 |
Cash and short-term investments of $196m on 2026-09-30; operating cash outflow about $55m a year; runway about 43 months at that burn, to Apr 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
Oruka Therapeutics Clarent Biopharma Abivax QED Therapeutics, a BridgeBio company Kymera Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.